Read by QxMD icon Read

Prostate biopsy

Douglas J Demetrick
Context Specimen misidentification is the most significant error in laboratory medicine, potentially accounting for hundreds of millions of dollars in extra health care expenses and significant morbidity in patient populations in the United States alone. New technology allows the unequivocal documentation of specimen misidentification or contamination; however, the value of this technology currently depends on suspicion of the specimen integrity by a pathologist or other health care worker. Objective To test the hypothesis that there is a detectable incidence of unsuspected tissue specimen misidentification among cases submitted for routine surgical pathology examination...
June 18, 2018: Archives of Pathology & Laboratory Medicine
Srinivas R Viswanathan, Gavin Ha, Andreas M Hoff, Jeremiah A Wala, Jian Carrot-Zhang, Christopher W Whelan, Nicholas J Haradhvala, Samuel S Freeman, Sarah C Reed, Justin Rhoades, Paz Polak, Michelle Cipicchio, Stephanie A Wankowicz, Alicia Wong, Tushar Kamath, Zhenwei Zhang, Gregory J Gydush, Denisse Rotem, J Christopher Love, Gad Getz, Stacey Gabriel, Cheng-Zhong Zhang, Scott M Dehm, Peter S Nelson, Eliezer M Van Allen, Atish D Choudhury, Viktor A Adalsteinsson, Rameen Beroukhim, Mary-Ellen Taplin, Matthew Meyerson
Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer (mCRPC), but there have been few whole-genome sequencing (WGS) studies of this disease state. We performed linked-read WGS on 23 mCRPC biopsy specimens and analyzed cell-free DNA sequencing data from 86 patients with mCRPC. In addition to frequent rearrangements affecting known prostate cancer genes, we observed complex rearrangements of the AR locus in most cases. Unexpectedly, these rearrangements include highly recurrent tandem duplications involving an upstream enhancer of AR in 70%-87% of cases compared with <2% of primary prostate cancers...
June 11, 2018: Cell
Mamoru Hashimoto, Naoki Matsumura, Takayuki Ohzeki, Sachiko Hongo, Koichi Sugimoto, Nobutaka Shimizu, Yasunori Mori, Takafumi Minami, Masahiro Nozawa, Kazuhiro Nose, Hideo Tahara, Kazuhiro Yoshimura, Hirotsugu Uemura
INTRODUCTION: We investigated whether the change in the neutrophil lymphocyte ratio (NLR) from the first to the last repeat prostate biopsy (ΔNLR) could be the diagnostic tool or not for prostate cancer (PCa) detection. MATERIALS AND METHODS: We retrospectively evaluated medical records of men who had undergone repeat prostate biopsy. The investigated parameters were white blood cell, neutrophil, lymphocyte counts, NLR at the last prostate biopsy, ΔNLR, prostate-specific antigen (PSA), PSA density (PSAD), and PSA velocity...
June 15, 2018: Urologia Internationalis
Anwar R Padhani, Jeffrey Weinreb, Andrew B Rosenkrantsz, Geert Villeirs, Baris Turkbey, Jelle Barentsz
CONTEXT: The Prostate Imaging-Reporting and Data System (PI-RADS) v2 analysis system for multiparametric magnetic resonance imaging (mpMRI) detection of prostate cancer (PCa) is based on PI-RADS v1, accumulated scientific evidence, and expert consensus opinion. OBJECTIVE: To summarize the accuracy, strengths and weaknesses of PI-RADS v2, discuss pathway implications of its use and outline opportunities for improvements and future developments. EVIDENCE ACQUISITION: For this consensus expert opinion from the PI-RADS steering committee, clinical studies, systematic reviews, and professional guidelines for mpMRI PCa detection were evaluated...
June 13, 2018: European Urology
M E Meunier, Y Neuzillet, C Radulescu, C Cherbonnier, J-M Hervé, M Rouanne, V Molinié, T Lebret
INTRODUCTION: The influence of the delay between prostate biopsy and radical prostatectomy for patients with localized prostate cancer is controversial. The objective of this study was to establish a time limit between prostate biopsy and radical prostatectomy beyond which the risks of upgradging and biochemical recurrence (BCR) are increased. MATERIAL AND METHODS: Between January 2013 and January 2017, a retrospective analysis of the clinical, biological and histological data of 513 patients treated with radical prostatectomy for localized prostate cancer was performed in a single center...
June 12, 2018: Progrès en Urologie
Nicholas P Meermeier, Kevin R Turner, Bryan R Foster, Csanád Várallyay, Jen-Jane Liu, Fergus V Coakley
PURPOSE: To investigate the concordance between dominant intraprostatic cancer seen on endorectal multiparametric MRI and confirmed by MRI-targeted biopsy with histopathological findings at radical prostatectomy, since existing literature has emphasized the miss rather than the concordance rate of MRI. MATERIALS AND METHODS: We retrospectively identified 20 patients who underwent radical prostatectomy after a dominant intraprostatic cancer focus was identified at endorectal multiparametric MRI and confirmed by MRI-targeted biopsy...
June 9, 2018: Clinical Imaging
Logan S Schwarzman, Michael R Abern, Daniel F Garvey, Gerald L Andriole, Stephen J Freedland, Daniel M Moreira
INTRODUCTION: Prostate biopsy complications have important consequences that may affect patient compliance with re-biopsy schemes; however, this has not been studied in earnest. Thus, we evaluated whether previous prostate biopsy-related complications and the type of complication were associated with repeat prostate biopsy compliance in a clinical trial with study-mandated systematic biopsies. MATERIALS AND METHODS: Retrospective analysis of 4,939 men ages 50-75 who underwent a 2-year prostate biopsy and were recommended to undergo the 4-year prostate re-biopsy in the Reduction by Dutasteride of prostate cancer Events (REDUCE) study...
June 12, 2018: Journal of Urology
Niranjan J Sathianathen, Karen M Kuntz, Fernando Alarid-Escudero, Nathan L Lawrentschuk, Damien M Bolton, Declan G Murphy, Christopher J Weight, Badrinath R Konety
PURPOSE: To perform a cost-effectiveness analysis of using Prostate Health Index (PHI), 4Kscore, SelectMDx and ExoDx Prostate IntelliScore (EPI) in men with an elevated PSA value to determine the need for biopsy. METHODS: We developed a decision-analytic model for men with an elevated PSA values (≥ 3ng/mL) where one of the biomarker tests was to determine which hypothetical individuals required a biopsy. In the current standard of care strategy, all individuals underwent a biopsy...
June 12, 2018: Journal of Urology
Antonio M Serafin, Angela Chinhengo, Pedro Fernandez, John M Akudugu
No unambiguous role of the involvement of uroplasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in prostate cancer has emerged, with current evidence suggesting that neither biomarker is likely of significant clinical value, save as an overall contributor. In this study, we attempt to discriminate prostate cancer from non-cancer in a cohort of plasma samples, using the Imubind ELISA assay. In this cohort, PAI-1 levels are higher in prostate cancer patients than healthy donors; uPA levels are higher in healthy donors than prostate cancer patients; and the uPA/PAI-1 ratio is higher in healthy donors than in prostate cancer patients...
May 2018: Discovery Medicine
Stephanie Markovina, Marshall W Meeks, Shahed Badiyan, Joel Vetter, Hiram A Gay, Alethea Paradis, Jeff Michalski, Gurdarshan Sandhu
Purpose: For high-risk prostate cancer (HR-PCa) in men with a life expectancy of at least 10 years, the National Comprehensive Cancer Network recommends radiation therapy (RT) plus androgen deprivation therapy (ADT) with category 1 evidence or radical prostatectomy (RP) as an acceptable initial therapy. Randomized evidence regarding which therapy is optimal for disease control is lacking for men with HR-PCa. We performed a propensity-score-matched comparison of outcomes for men with localized HR-PCa treated with primary RT or RP...
April 2018: Advances in Radiation Oncology
Vladimir Mouraviev, Michael McDonald
INTRODUCTION: The changing face of current infection phenotypes from planktonic to biofilm type has been developed implicating bacterial biofilms in recurrent infection. To date, no specific medical treatment exists to specifically target biofilms in the human host. Similarly, the identification of a biofilm has relied upon the analysis of tissue samples with electron microscopy or DNA identification with polymerase chain reaction (PCR) and sequencing. Standard culture and sensitivity test is not able to detect a presence of biofilms...
June 2018: Canadian Journal of Urology
Sriram Somanchi, Daniel B Neill, Anil V Parwani
Advances in medical imaging technology have created opportunities for computer-aided diagnostic tools to assist human practitioners in identifying relevant patterns in massive, multiscale digital pathology slides. This work presents Hierarchical Linear Time Subset Scanning, a novel statistical method for pattern detection. Hierarchical Linear Time Subset Scanning exploits the hierarchical structure inherent in data produced through virtual microscopy in order to accurately and quickly identify regions of interest for pathologists to review...
June 13, 2018: Statistics in Medicine
Matthew J Atherton, Kyle B Stephenson, Fanny Tzelepis, David Bakhshinyan, Jake K Nikota, Hwan Hee Son, Anna Jirovec, Charles Lefebvre, Anna Dvorkin-Gheva, Ali A Ashkar, Yonghong Wan, David F Stojdl, Eric C Belanger, Rodney H Breau, John C Bell, Fred Saad, Sheila K Singh, Jean-Simone Diallo, Brian D Lichty
Prostate cancer (PCa) was estimated to have the second highest global incidence rate for male non-skin tumors and is the fifth most deadly in men thus mandating the need for novel treatment options. MG1-Maraba is a potent and versatile oncolytic virus capable of lethally infecting a variety of prostatic tumor cell lines alongside primary PCa biopsies and exerts direct oncolytic effects against large TRAMP-C2 tumors in vivo . An oncolytic immunotherapeutic strategy utilizing a priming vaccine and intravenously administered MG1-Maraba both expressing the human six-transmembrane antigen of the prostate (STEAP) protein generated specific CD8+ T-cell responses against multiple STEAP epitopes and resulted in functional breach of tolerance...
2018: Oncoimmunology
Sofie Tops, Marlie Bruens, Sacha van Mook-Vermulst, Diane Lamers-Jansen, Tobias Engel, Ger van den Brink, Rob van Duuren, Heiman F L Wertheim, Eva Kolwijck
Background and Objectives: A rectal culture-guided antimicrobial prophylaxis strategy may prevent infections after transrectal ultrasound-guided prostate biopsy (TRUSP). The use of selective culture media could assist the choice of appropriate antibiotic prophylaxis. The objective of our study was to evaluate the performance of four selective media used for guidance of oral antibiotic prophylaxis in TRUSP. Methods: In this prospective validation study, we used MacConkey media with vancomycin plus one of the following antibiotics: ciprofloxacin (McC3 + CIP/V), trimethoprim (McC3 + TMP/V), fosfomycin (McC3 + FOF/V) or mecillinam/amoxicillin/clavulanic acid (McC3 + MEC/V)...
June 13, 2018: Journal of Clinical Microbiology
Ying Chang, Jingchun Yang, Hua Hong, Huijuan Ma, Xin Cui, Li Chen
To evaluate the performance of a combination of real-time strain elastography (RTSE) and contrast-enhanced transrectal ultrasound (CETRUS) for prostate cancer detection. Patients with serum prostate-specific antigen (PSA) levels of ≥4.0 ng/ml were prospectively enrolled between June 2014 and December 2016. 153 prostate nodules diagnosed by conventional ultrasound were prospectively enrolled and examined by CETRUS and RTSE before a biopsy. Multivariate logistic regression models were established for CETRUS, and CETRUS combined with RTSE to diagnose prostate malignancy...
June 2018: Aging and Disease
Maria Gosein, Emily Pang, Silvia Chang, Peter Black, Larry Goldenberg, Alison Harris, Jason Yasenjiang, Masoud Yousefi
No abstract text is available yet for this article.
June 9, 2018: Canadian Association of Radiologists Journal, Journal L'Association Canadienne des Radiologistes
M H Choi, Y J Lee, S E Jung, S E Rha, J Y Byun
AIM: To validate the diagnostic accuracy of Prostate Imaging-Reporting and Data System (PI-RADS) version 2 in detecting clinically significant prostate cancer (csPCa, Gleason score ≥7) on prebiopsy biparametric MRI (bpMRI) in patients with different prostate-specific antigen (PSA) levels. MATERIALS AND METHODS: This retrospective study included 184 patients who underwent prebiopsy bpMRI followed by transrectal ultrasonography-guided biopsy between June 2015 and February 2017...
June 9, 2018: Clinical Radiology
Xiang-Ke Niu, Xue-Hui Chen, Zhi-Fan Chen, Lin Chen, Jun Li, Tao Peng
OBJECTIVE: The purpose of this study was to perform a systematic review and meta-analysis to estimate the diagnostic performance of biparametric MRI (bpMRI) for detection of prostate cancer (PCa). MATERIALS AND METHODS: Two independent reviewers performed a systematic review of the literature published from January 2000 to July 2017 by using predefined search terms. The standard of pathologic reference was established at prostatectomy or prostate biopsy. The numbers of true- and false-positive and true- and false-negative results were extracted...
June 12, 2018: AJR. American Journal of Roentgenology
Kimberly A Maciolek, Sara L Best, Vania Lopez, Natasza Posielski, Margaret Knoedler, Wade A Bushman, David F Jarrard, Tracy M Downs, E Jason Abel, Kyle A Richards
PURPOSE: To prospectively implement a prostate biopsy protocol to identify high-risk patients for bleeding or infectious complications and use risk-tailored antimicrobials, patient education, and postbiopsy monitoring with the objective of reducing complications. MATERIALS AND METHODS: Overall, 637 consecutive patients from June 2014 to August 2016 underwent prostate biopsy at our Veterans Affairs hospital. In the protocol cohort, patients were screened before biopsy and prophylaxis was tailored (high risk = ceftriaxone; low risk = ciprofloxacin)...
June 7, 2018: Urologic Oncology
Felix Preisser, Sebastiano Nazzani, Marco Bandini, Michele Marchioni, Zhe Tian, Francesco Montorsi, Fred Saad, Alberto Briganti, Thomas Steuber, Lars Budäus, Hartwig Huland, Markus Graefen, Derya Tilki, Pierre I Karakiewicz
OBJECTIVES: To investigate lymph node invasion (LNI) rates in prostate cancer (PCa) patients. Recent studies demonstrated an inverse stage migration in PCa patients toward more advanced and unfavorable diseases. We hypothesized that this trend is also evident in LNI rates, in PCa patients treated with radical prostatectomy (RP) and pelvic lymph node dissection (PLND). PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2014), we identified patients who underwent RP and PLND...
June 7, 2018: Urologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"